Gilead says its oncology and inflammation portfolio has reached critical mass after series of acquisitions

Gilead Sciences CEO Daniel O’Day told Fierce that the company’s push into oncology and inflammation has now reached a point of critical mass, with a pipeline that spans early research to late‑stage development.

He highlighted three major biotech purchases that built the foundation: the $12 billion acquisition of Kite Pharma in 2019, which brought the lymphoma therapy Yescarta; the $21 billion buyout of Immunomedics in 2020, adding the breast‑cancer drug Trodelvy; and the $4.3 billion purchase of CymaBay Therapeutics in 2024, delivering the primary biliary cholangitis treatment Livdelzi.

Looking ahead, O’Day said any future M&A will be selective, aimed only at complementing the existing platform rather than driving further large‑scale expansion.